is phentermine a glp-1 receptor agonist vs GLP-1: how the two biggest weight loss medication classes compare New global study ranks most

KUST-KH2023012Y) Yunnan Basic Research Program (grant number 202401AY070001-252)

Stopping Treatment: Weight regain often occurs after discontinuation, typically two-thirds of lost weight within a year

Looking for support with Weight loss

Hutch CR, Sandoval D

Orthosteric binding of incretin peptides to the N-terminus (extracellular) region of the receptors causes a conformational change, stabilizing a binding site in the intracellular region that allows coupling to and activation of heterotrimeric guanine nucleotide-binding protein (G proteins) ( a and subunits to dissociate triggering different signalling cascades

However, due to its invasiveness, it should be offered preferentially to patients with exhausted non-pharmacological and pharmacological treatment options